非小细胞肺癌组织中表皮生长因子受体基因突变与ERCC1和RRM1mRNA表达的关系  

Relations of epidermal growth factor receptor gene mutation and the mRNA expression of ERCC1 and RRM1 in non-small cell lung cancer tissue

作　　者：田玉旺[1] 许春伟[1] 高文斌[2] 张玉萍[3] 李扬[4] 亓岽东[2] 

机构地区：[1]解放军北京军区总医院病理科,100700 [2]大连大学附属中山医院肿瘤科,116001 [3]山东省潍坊市人民医院病理科,261041 [4]解放军北京军区总医院肿瘤内科诊治中心,100700

出　　处：《中华肺部疾病杂志（电子版）》2014年第1期27-31,共5页Chinese Journal of Lung Diseases(Electronic Edition)

基　　金：吴阶平医学基金会临床科研专项资助基金项目(320.6750.1360)

摘　　要：目的探讨非小细胞肺癌(NSCLC)组织中人表皮生长因子受体(EGFR)基因突变与切除修复交叉互补蛋白1(ERCC1)和核苷酸还原酶亚单位M1(RRM1)mRNA表达的关系。方法应用实时荧光定量PCR方法检测257例NSCLC组织中EGFR基因突变、ERCC1和RRM1mRNA的表达。结果 NSCLC组织中EGFR基因突变率占49.03%(126/257),在女性和不吸烟患者中较高(P<0.05);ERCC1mRNA高表达占47.47%(122/257),RRM1mRNA高表达占61.87%(159/257)。与未检测到EGFR基因突变的NSCLC患者比较,EGFR基因突变中ERCC1mRNA低表达者多见(P<0.05);NSCLC组织中,EGFR基因突变与RRM1mRNA表达水平无关(P>0.05);ERCC1mRNA表达水平与RRM1mRNA表达水平无关(P<0.05)。结论 NSCLC组织中EGFR基因突变患者ERCC1倾向低表达,可能受益于以铂类药物为基础的化疗。Objective To Explore relationship between human epidermal growth factor receptor （EGFR） gen mutation and the mRNA expression of excision repair cross complement protein 1 （ERCC1） and ribonucleotide reductase subunit M1 （ RRM1 ） in non-small cell lung cancer（NSCLC） tissue. Methods It was tested that 257 cases in NSCLC tissue expression of EGFR mutations, ERCC1 and RRMlmRNA by real-time fluorescent quantitative PCR method. Results EGFR mutation rate in NSCLC tissue was 49.03%, higher in women and non-smoking patients （P 〈 0.05） and ERCClmRNA expression was 47. 47% （122/257） , RRMlmRNA overexpression was 61. 87% （159/257）. EGFR mutation was not detected in patients with NSCLC, ERCClmRNA low expression in EGFR gene mutation （P 〈 0. 05） ; in NSCLC tissue and the expression of EGFR gene mutation and RRMlmRNA has nothing to do （ P 〉 0. 05 ） , the expression of RRMlmRNA was not related to the expression of ERCClmRNA （P 〉 0.05）. Conclusions Low ERCC1 expression in NSCLC patients with EGFR mutations may benefit from a platinum-based chemotherapy.

关 键 词：非小细胞肺癌 人表皮生长因子受体 切除修复交叉互补基因 核苷酸还原亚单位M1 分子检测 个体化治疗 

分 类 号：R734.2[医药卫生—肿瘤] R563[医药卫生—临床医学]